CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- Ionis Pharmaceuticals, Inc.
- Study ID
- NCT05681351
- Phase
- PHASE3
- Status
- Active Not Recruiting
Conditions
- Severe Hypertriglyceridemia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Olezarsen — DRUGAdministered as SC injection.
Study Details
The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.
Key Dates
- Start date
- Dec 13, 2022
- Status verified
- Nov 2025
- Primary completion
- Mar 31, 2027
- Completion
- Mar 31, 2027
Study Design
- Enrollment
- 885 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: OlezarsenParticipants who completed either ISIS 678354-CS5 (NCT05079919) or ISIS 678354-CS6 (NCT05552326) study would be enrolled to receive olezarsen, subcutaneous (SC) injection, once every 4 weeks from Week 1 through Week 153.
Primary Outcome Measure
Proportion of Participants With Change in Clinical Laboratory Values From Baseline to Week 53, From Baseline to Week 105, and From Baseline to Week 157 [ Time Frame: Baseline up to Week 157 ]
Locations (65)
Find similar trials in Los Angeles, CA
Related Studies
- Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute PancreatitisPHASE3 · Recruiting · Arrowhead Pharmaceuticals · Los Angeles, California
- A Study of Solbinsiran (LY3561774) in Participants With Severe HypertriglyceridemiaPHASE2 · Recruiting · Eli Lilly and Company · Phoenix, Arizona
- A Study to Assess the Safety, Tolerability and Efficacy of ION775PHASE2 · Recruiting · Ionis Pharmaceuticals, Inc. · Lincoln, California